Vor Biopharma Inc
VOR
NGS
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
5.26
USD
-0.13
(-2.41%)
Optionable: No Market Cap: 200 M 90-day average vol: 130,420
Previous close: 5.39 Open: 5.4172 Bid: 8.56 Ask: 8.56
52 week range
3.83 18.52
Last updated: Wednesday 17th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 1.17 |
PE Ratio (TTM) | -2.50 |
Book Value per Share ($) | 5.17 |
5 Year PE Range | -5.5 , -5.8 |
Returns
7 Day Return | 9.58% | |
1 Month Return | 3.54% | |
3 Month Return | 24.64% | |
1 Year Return | -57.03% | |
3 Year Return | -85.97% | |
5 Year Return | -85.97% | |
YTD Return | -54.73% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 55.22 |
14 Day SMA ($) | 4.97 |
14 Day EMA ($) | 5.06 |
Money Flow Index | 40.13 |
Average True Range | 0.49 |
50 Day SMA ($) | 5.06 |
200 Day SMA ($) | 8.11 |
ADX | 13.33 |
MACD | 0.05 |
Growth
Free Cash Flow QoQ Growth | 32.84% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 27.08% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Vor to Participate in Three Upcoming Investor Conferences
Yahoo Finance 2/28/2022
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Yahoo Finance 2/11/2022
Vor to Participate in Two Upcoming Investor Conferences
Yahoo Finance 1/4/2022
Vor Biopharma granted FDA’s orphan drug designation for leukemia drug
Seeking Alpha 12/17/2021
Vor initiated with a buy at Baird on potential of leukemia therapy; sees 193% upside
Seeking Alpha 12/9/2021
Vor Biopharma a buy at Oppenheimer on engineered stem cells; sees 165% upside
Seeking Alpha 12/2/2021
Vor Biopharma (VOR) Investor Presentation - Slideshow
Seeking Alpha 12/1/2021
Vor to Participate in the JMP Securities Hematology and Oncology Summit
Yahoo Finance 11/29/2021
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital
Yahoo Finance 11/25/2021
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
Yahoo Finance 11/19/2021
Vor Biopharma (VOR) Investor Presentation - Slideshow
Seeking Alpha 11/19/2021
Vor Biopharma Insider Sold Over $5.0M In Company Stock
Yahoo Finance 11/19/2021
Does Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect?
Yahoo Finance 11/15/2021
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
Yahoo Finance 11/11/2021
Vor Biopharma EPS beats by $0.12
Seeking Alpha 11/10/2021
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
Yahoo Finance 11/10/2021
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
Yahoo Finance 11/9/2021
Vor to Present New Platform and Preclinical Data at ASH
Yahoo Finance 11/4/2021
Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT
Yahoo Finance 10/19/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 16.616
Financials
VOR Income Statement
Annual
| Invalid date | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | |
| Cost of sales | -20000 | -91000 | -605000 | -1 M | |
| Gross operating profit | 0 | 0 | 0 | 0 | |
| Selling Gen & administrative expense | 427000 | 4 M | 12 M | 21 M | |
| Research & development expense | 2 M | 6 M | 32 M | 48 M | |
| Operating income | -3 M | -10 M | -43 M | -69 M | |
| floaterest income | 0 | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | 0 | |
| Other income net | -289000 | 32000 | 0 | 0 | |
| Pre-tax Income (EBT) | -4 M | -11 M | -43 M | -69 M | |
| Income taxes | 0 | 0 | 0 | 0 | |
| Net income from total operations | -4 M | -11 M | -43 M | -69 M | |
| Minority floaterest | 0 | 0 | 0 | 0 | |
| Total net income | -4 M | -11 M | -43 M | -69 M | |
| Preferred dividends | N/A | 2 M | 6 M | 1 M | |
| Net income available for common | -4 M | -13 M | -49 M | -70 M | |
| Depreciation | 20000 | 91000 | 605000 | 1 M | |
| Amortization | 0 | 0 | 0 | 0 | |
| Operating income before depreciation (EBITDA) | -3 M | -10 M | -43 M | -68 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | |
| Basic EPS total | -0.73 | -1.91 | -1.42 | -2.1 | |
| Diluted EPS total | -0.73 | -1.91 | -1.42 | -2.1 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!